Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

An evidence-based review of skin cancer rates on biologic therapies.

Kamangar F, Neuhaus IM, Koo JY.

J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064. Review.

PMID:
22188512
2.

Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:22-31. doi: 10.1111/j.1468-3083.2012.04520.x. Review.

PMID:
22512677
3.

Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.

Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, Alsina M, Herrera-Ceballos E, Gómez-García FJ, Ferrán M, López-Estebaranz JL, Hernanz JM, Belinchón-Romero I, Vilar-Alejo J, Rivera R, Carrascosa JM, Carazo C.

Arch Dermatol. 2012 Apr;148(4):463-70. doi: 10.1001/archdermatol.2011.2768.

PMID:
22508869
4.

Screening for skin cancer.

Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT.

Am J Prev Med. 2001 Apr;20(3 Suppl):47-58. Review.

PMID:
11306232
5.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
6.

[Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology].

Beani JC, Jeanmougin M.

Ann Dermatol Venereol. 2010 Jan;137(1):21-31. doi: 10.1016/j.annder.2009.12.004. Epub 2009 Dec 29. Review. French.

PMID:
20110064
7.

A systematic review of treatments for hidradenitis suppurativa.

Rambhatla PV, Lim HW, Hamzavi I.

Arch Dermatol. 2012 Apr;148(4):439-46. doi: 10.1001/archdermatol.2011.1950. Epub 2011 Dec 19. Review.

PMID:
22184715
8.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

9.
10.

Risk of cancer in patients with psoriasis on biological therapies: a systematic review.

Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH.

Br J Dermatol. 2017 Jul 19. doi: 10.1111/bjd.15830. [Epub ahead of print] Review.

PMID:
28722163
11.

Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile.

Ganzetti G, Campanati A, Molinelli E, Offidani A.

Curr Drug Saf. 2016;11(1):12-21. Review.

PMID:
26463243
12.

[What's New in Dermatological Therapy?].

Bachelez H.

Ann Dermatol Venereol. 2015 Dec;142 Suppl 3:S49-54. doi: 10.1016/S0151-9638(16)30006-0. Review. French.

PMID:
26792414
13.

A reply to: 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials'.

Amin M, No DJ, Wu JJ.

Br J Dermatol. 2017 Aug;177(2):580-581. doi: 10.1111/bjd.15620. Epub 2017 Jun 6. No abstract available.

PMID:
28456136
14.

Innovations in the treatment of psoriasis and non-melanoma skin cancers.

van de Kerkhof PC.

J Dermatolog Treat. 2013 Jun;24(3):161. doi: 10.3109/09546634.2013.795212. No abstract available.

PMID:
23621434
15.

Immunogenicity in biologic therapy: implications for dermatology.

Carrascosa JM.

Actas Dermosifiliogr. 2013 Jul-Aug;104(6):471-9. doi: 10.1016/j.ad.2013.02.005. Epub 2013 Apr 25. English, Spanish.

PMID:
23622932
16.

Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors.

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Dec;177(6):1766-1767. doi: 10.1111/bjd.16043. Epub 2017 Nov 22. No abstract available.

PMID:
28990164
17.
18.

Show me the evidence!

Hagland M.

Biotechnol Healthc. 2006 Aug;3(4):33-8.

19.

Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.

Bardazzi F, Magnano M, Campanati A, Loconsole F, Carpentieri A, Potenza C, Bernardini N, Di Lernia V, Carrera C, Raone B, Patrizi A, Loi C.

Acta Derm Venereol. 2017 Aug 31;97(8):989-990. doi: 10.2340/00015555-2698. No abstract available.

20.

Building a value-based approach to biologic drugs.

Clarke JL, Skoufalos A, Nash DB, Toppy E.

Biotechnol Healthc. 2009 Aug;6(3):31-5.

Supplemental Content

Support Center